Zobrazeno 1 - 10
of 25
pro vyhledávání: '"H. M. Reisner"'
Publikováno v:
International Endodontic Journal. 30:155-159
Publikováno v:
Scopus-Elsevier
SummaryInhibiting antibodies in patients with hemophilia A pose a significant therapeutic dilemma in the treatment of bleeding episodes. The genetic factors which predispose hemophiliacs to inhibitors and the optimal method for inhibitor suppression
Autor:
Michael A. Jarvis, C. L. Ziaja, C. M. Suzuki, D. J. DePianto, Charles F. Abildgaard, Jennifer Brown, Jerry S. Powell, K. W. Jolly, H. M. Reisner, Janet Harrison, L. G. Levin
Publikováno v:
Scopus-Elsevier
SummaryHemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25% of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rF
Publikováno v:
Vox sanguinis. 92(3)
Background and Objectives Intravenous immunoglobulin (IVIG) is used for an increasingly diverse number of therapeutic applications as an immunomodulation drug. Although it has demonstrated therapeutic effectiveness, the mechanism of action of IVIG in
Publikováno v:
International endodontic journal. 30(3)
Lipopolysaccharide (LPS), a cell wall component of Gram negative anaerobic bacteria, has been implicated in the pathogenesis of periapical disease resulting from infected root canals. Calcium hydroxide [Ca(OH)2] has been shown to be an effective medi
Autor:
M A, Jarvis, L G, Levin, J A, Harrison, D J, DePianto, C M, Suzuki, C L, Ziaja, J E, Brown, K W, Jolly, H M, Reisner, C F, Abildgaard, J S, Powell
Publikováno v:
Thrombosis and haemostasis. 75(2)
Hemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25% of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rFVIII) i
Publikováno v:
Advances in experimental medicine and biology. 386
Publikováno v:
Journal of Endodontics. 25:303
Publikováno v:
Journal of Biological Chemistry. 255:8599-8605
Publikováno v:
Scopus-Elsevier
Two monoclonal antibodies (MAb 53, MAb D7) were produced, each having specificity for Factor VIII-related antigen (FVIIIR:Ag), but exhibiting no inhibitory effect on either procoagulant activity or the ability of von Willebrand factor to agglutinate